Antigen- Specific Immune Tolerance Drug Development Summit 2018

Antigen- Specific Immune Tolerance Drug Development Summit is organized by Hanson Wade and will be held during Apr 24 - 26, 2018 at Aloft Boston Seaport, Boston, Massachusetts, United States of America.

Course Description :
As the first generation of antigen-specific immune tolerance therapies enter clinics and with excitement around recent partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to be able to meet and share knowledge.

The 1st Antigen-Specific Immune Tolerance Drug Development Summit is that forum, and has a brand-new agenda that can help you successfully overcome the scientific, product development and commercialization challenges currently being faced.

The clinical heterogeneity of the more than 80 autoimmune diseases presents a significant challenge with respect to the development of therapies designed to re-establish self-tolerance. As the first generation of antigen-specific immune tolerance therapies enters the clinic and excitement around the recent deals, partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for regulatory agencies, large pharma, pioneering biotech and academia to unite. With opportunity aplenty for those that can successfully translate ground breaking science into a novel class of therapies to treat autoimmunity, the inaugural Antigen-Specific Immune Tolerance Drug Development Summit 2018 will be dedicated to determining mechanisms of action and validation of more predictable pre-clinical models that can be effectively translated into a human clinical setting. Furthermore, as the current standard of care for autoimmunity leads to adverse side effects, discover the latest clinical data, manufacturing and commercialization strategies to ensure this novel class of antigen-specific immune tolerance therapeutics is safely and effectively delivered to the patient market.

Speakers: Amy S. Rosenberg (CDER/FDA), Arpita Maiti (Pfizer, Inc.), Lachy McLean (Takeda Pharmaceuticals), Jose M. Carballido (Novartis), Jack A. Ragheb (Eli Lilly & Co), Lawrence A. Steinman (Tolerion), Laurence A. Turka (Immune Tolerance Network), Matthias von Herrath (Novo Nordisk), Kei Kishimoto (Selecta Biosciences), Jonathan Zalevsky (Nektar Therapeutics), Francisco J. Quintana (AnTolRx)

Additional details will be posted as soon as they are available.